[go: up one dir, main page]

AR039166A1 - Composiciones de venlafaxina base - Google Patents

Composiciones de venlafaxina base

Info

Publication number
AR039166A1
AR039166A1 ARP030101074A ARP030101074A AR039166A1 AR 039166 A1 AR039166 A1 AR 039166A1 AR P030101074 A ARP030101074 A AR P030101074A AR P030101074 A ARP030101074 A AR P030101074A AR 039166 A1 AR039166 A1 AR 039166A1
Authority
AR
Argentina
Prior art keywords
venlafaxine
base
compositions
liquid phase
pharmaceutical composition
Prior art date
Application number
ARP030101074A
Other languages
English (en)
Inventor
Escoi Joan Cucala
Luengo Montserrat Gallego
Marinus Jacobus Maria Oosterbaan
Frantisek Picha
Original Assignee
Synthon Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthon Bv filed Critical Synthon Bv
Publication of AR039166A1 publication Critical patent/AR039166A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Composición farmacéutica que comprende una venlafaxina base sólida y un excipiente farmacéuticamente aceptable, a un procedimiento para preparar una composición de venlafaxina, que comprende dispersar venlafaxina base en un portador de fase líquida; y solidificar dicha fase líquida para formar una dispersión sólida de venlafaxina, y al uso de una composición farmacéutica como un medicamento.
ARP030101074A 2002-03-28 2003-03-27 Composiciones de venlafaxina base AR039166A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36773602P 2002-03-28 2002-03-28

Publications (1)

Publication Number Publication Date
AR039166A1 true AR039166A1 (es) 2005-02-09

Family

ID=28675392

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP030101074A AR039166A1 (es) 2002-03-28 2003-03-27 Composiciones de venlafaxina base
ARP030101073A AR039165A1 (es) 2002-03-28 2003-03-27 Venlafaxina base

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP030101073A AR039165A1 (es) 2002-03-28 2003-03-27 Venlafaxina base

Country Status (5)

Country Link
US (2) US20030191347A1 (es)
EP (1) EP1487429A2 (es)
AR (2) AR039166A1 (es)
AU (2) AU2003226748A1 (es)
WO (2) WO2003082262A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060246132A1 (en) * 2003-02-07 2006-11-02 Fjalar Johannsson Sustained release formulations of venlafaxine
US20050048118A1 (en) * 2003-07-25 2005-03-03 Joan Cucala Escoi Modified release venlafaxine hydrochloride tablets
EP1523979A1 (en) * 2003-10-13 2005-04-20 Wyeth Extended release pharmaceutical dosage form
US20050142203A1 (en) * 2003-12-30 2005-06-30 Grant Heinicke Oral dosage formulations of active pharmaceutical ingredients and methods of preparing the same
NZ548504A (en) * 2004-02-04 2009-03-31 Alembic Ltd Extended release coated microtablets of venlafaxine hydrochloride
AU2005212166A1 (en) * 2004-02-06 2005-08-25 Wyeth Multiparticulate O-desmethylvenlafaxine salts and uses thereof
AU2005209948B2 (en) 2004-02-06 2009-09-10 Pharmatel (R&D) Pty Limited Use of aminosalicylates in diarrhoea-predominent Irritable Bowel Syndrome
WO2005112901A1 (en) * 2004-05-21 2005-12-01 Lupin Ltd. Novel extended release composition of venlafaxine hydrochloride containing polyvinyl acetate
DE602005022175D1 (de) * 2004-05-28 2010-08-19 Salix Pharmaceuticals Inc Prävention, behandlung und linderung strahlungsinduzierter enteritis
CN1955159B (zh) 2005-06-17 2010-11-24 山东绿叶制药有限公司 用于阻断5-羟色胺以及去甲基肾上腺素再摄取的化合物,其制备方法及其用途
RU2007148195A (ru) * 2005-07-15 2009-08-20 Вайет (Us) Пероральные дозированные формы о-десметилвенлафаксин сукцината повышенной биодоступности с отсроченным высвобождением
CN102670626A (zh) * 2005-08-24 2012-09-19 萨利克斯药品公司 巴柳氮制剂及其生产和应用
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US7452872B2 (en) 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
CN102212014B (zh) * 2010-04-09 2013-12-25 江苏豪森医药集团有限公司 O-去甲基-文拉法辛的谷氨酸盐的晶型、其制备方法及其在医药上的应用
CA2788526A1 (en) * 2010-05-14 2011-11-17 Alembic Limited Extended release formulations of desvenlafaxine base
MY160607A (en) 2010-10-01 2017-03-15 Shan Dong Luye Pharm Co Ltd Polymorphs of 4-[2-dimethylamino-1-(1-hydroxycyclohexyl) ethyl]phenyl 4-methylbenzoate hydrochloride, methods for preparing the same and use of the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4535186A (en) * 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
GB8902209D0 (en) * 1989-02-01 1989-03-22 Wyeth John And Brother Limited Preparation of cyclohexanol derivatives and novel thioamide intermediates
ES2273764T3 (es) * 1993-06-28 2007-05-16 Wyeth Nuevos tratamientos que utilizan derivados de fenetilamina.
US6274171B1 (en) * 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
UA77145C2 (en) * 1997-11-05 2006-11-15 Wyeth Corp Extended release dosage formulation
US6197828B1 (en) * 1998-12-01 2001-03-06 Sepracor, Inc. Derivatives of (+)-venlafaxine and methods of preparing and using the same
US20020022662A1 (en) * 1999-06-15 2002-02-21 American Home Products Corporation Enantiomers of O-desmethyl venlafaxine
GEP20053427B (en) * 1999-12-23 2005-01-25 Pfizer Prod Inc Pharmaceutical Compositions Providing Enhanced Drug Concentrations
US20020183553A1 (en) * 2000-10-19 2002-12-05 Ben-Zion Dolitzky Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
PL365895A1 (en) * 2000-10-19 2005-01-10 Teva Pharmaceutical Industries Ltd. Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
BR0100334A (pt) * 2001-01-17 2002-09-24 Diffucap Chemobras Quimica E F Processo para a preparação de composições de liberação programada contendo venlafaxina e o produto resultante

Also Published As

Publication number Publication date
WO2003082806A1 (en) 2003-10-09
US20030190352A1 (en) 2003-10-09
AR039165A1 (es) 2005-02-09
WO2003082262A2 (en) 2003-10-09
WO2003082262A3 (en) 2004-07-29
EP1487429A2 (en) 2004-12-22
AU2003226748A8 (en) 2003-10-13
AU2003226748A1 (en) 2003-10-13
US20030191347A1 (en) 2003-10-09
AU2003226752A1 (en) 2003-10-13

Similar Documents

Publication Publication Date Title
AR039166A1 (es) Composiciones de venlafaxina base
CL2004001267A1 (es) Compuestos derivados de quinazolina, inhibidor de quinasa; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso para preparar un medicamento para tratar trastornos proliferativos celulares tales como ateroesclerosis,
UY31406A1 (es) "producto de dispersion solida que contiene un compuesto a base de n-aril urea".
BRPI0409133B8 (pt) preparações farmacêuticas estavéis compreendendo metilnaltrexona
UY27740A1 (es) Nuevos compuestos
CL2009001766A1 (es) Composicion farmaceutica solida para administracion oral que comprende: un taxano sustancialmente amorfo definido, un portador hidrofilico definido y un tensoactivo definido; metodo para preparar la composicion; y su uso para tratar una enfermedad neoplasica.
BRPI0015567B8 (pt) composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica
BR0112311A (pt) Compostos e composições para liberar agentes ativos, forma de dosagem unitária, método para preparar ditas composições e seu uso
AR007827A1 (es) 3-ureido-piridofuranos y -piridotiofenos, procedimiento para su preparacion, composicion que los comprende y uso de dichos compuestos para lapreparacion de medicamentos.
AR034813A1 (es) Composiciones farmaceuticas y uso de las mismas
WO2003035051A3 (en) The use of proton sequestering agents in drug formulations
UA90708C2 (ru) Таблетки с улучшенной дисперсностью лекарственного вещества
TW200501965A (en) Highly pure fondaparinux sodium composition,process for preparing said composition and pharmaceutical compositions containing it as active principle
CL2009000980A1 (es) Uso de (s)-n-(2-(1,6,8-tetrahidro-2h-inden[5,4-b]furan-8-il)etil]propionamida en combinacion con una o más drogas seleccionadas de un grupo definido para preparar un medicamento útil para la prevencion o tratamiento de la depresión o desórdenes de ansiedad (divisional de la solicitud 749-2006).
IL164440A0 (en) New pharmaceutical composition containing fibanserin polymorph a
NO20042158L (no) Substituert 4-fenyl-tetrahydroisokinoliner, fremgangsmate for fremstilling derav, anvendelse derav som medikamenter, i tillegg til medikamenter inneholdende samme
AR027360A1 (es) Composicion farmaceutica
UY29701A1 (es) Formulaciones líquidas para la administración controlada de derivados de bencisoxazol
TW200505436A (en) Modified release pharmaceutical compositions and the processes for preparing them
UY29896A1 (es) Nuevos derivados de cromano, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
SE0302924D0 (sv) Pharmaceutical composition having a cationic excipient
BR0111669A (pt) Novos compostos
MX2008001560A (es) Nuevos compuestos analogos de la camptotecina, un procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
WO2004069145A3 (en) Anticancer compounds, process for their preparation and pharmaceutical compositions containing them
UY29892A1 (es) Nuevos derivados de cromano, composiciones farmaceuticas conteniendolos, procesos de preparacion y aplicaciones

Legal Events

Date Code Title Description
FB Suspension of granting procedure